Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLCO1A2 | SNV | Missense_Mutation | novel | c.1843C>T | p.Pro615Ser | p.P615S | P46721 | protein_coding | tolerated(0.07) | benign(0.443) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
SLCO1A2 | SNV | Missense_Mutation | | c.1069N>G | p.Leu357Val | p.L357V | P46721 | protein_coding | tolerated(0.29) | benign(0.393) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SLCO1A2 | SNV | Missense_Mutation | novel | c.608C>A | p.Ala203Asp | p.A203D | P46721 | protein_coding | deleterious(0.02) | possibly_damaging(0.694) | TCGA-AC-A6IX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SLCO1A2 | SNV | Missense_Mutation | | c.1561A>G | p.Ser521Gly | p.S521G | P46721 | protein_coding | tolerated(0.17) | benign(0.071) | TCGA-B6-A0IB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
SLCO1A2 | SNV | Missense_Mutation | novel | c.475N>A | p.Val159Met | p.V159M | P46721 | protein_coding | deleterious(0.02) | benign(0.297) | TCGA-E2-A14N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
SLCO1A2 | deletion | In_Frame_Del | novel | c.1748_1762delGTGGTGAGTCAGGGG | p.Cys583_Ala588delinsSer | p.C583_A588delinsS | P46721 | protein_coding | | | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLCO1A2 | SNV | Missense_Mutation | novel | c.330N>A | p.Met110Ile | p.M110I | P46721 | protein_coding | tolerated(0.11) | possibly_damaging(0.838) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
SLCO1A2 | SNV | Missense_Mutation | | c.1148N>A | p.Thr383Asn | p.T383N | P46721 | protein_coding | tolerated(1) | benign(0.013) | TCGA-C5-A7UE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
SLCO1A2 | SNV | Missense_Mutation | | c.1147N>T | p.Thr383Ser | p.T383S | P46721 | protein_coding | tolerated(0.9) | benign(0.088) | TCGA-C5-A7UE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
SLCO1A2 | SNV | Missense_Mutation | rs763423819 | c.1549T>C | p.Ser517Pro | p.S517P | P46721 | protein_coding | deleterious(0) | probably_damaging(0.936) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6579 | SLCO1A2 | TRANSPORTER, DRUGGABLE GENOME | | TESTOSTERONE | TESTOSTERONE | 8779895 |
6579 | SLCO1A2 | TRANSPORTER, DRUGGABLE GENOME | inhibitor | 135652711 | RIFAMPIN | |
6579 | SLCO1A2 | TRANSPORTER, DRUGGABLE GENOME | | HORMONES | | 8779894 |
6579 | SLCO1A2 | TRANSPORTER, DRUGGABLE GENOME | | hmg coa reductase inhibitors | | |
6579 | SLCO1A2 | TRANSPORTER, DRUGGABLE GENOME | inhibitor | 178101291 | | |
6579 | SLCO1A2 | TRANSPORTER, DRUGGABLE GENOME | | rocuronium | ROCURONIUM | 28409297 |
6579 | SLCO1A2 | TRANSPORTER, DRUGGABLE GENOME | | methotrexate | METHOTREXATE | 21317831 |
6579 | SLCO1A2 | TRANSPORTER, DRUGGABLE GENOME | | 178101458 | | |
6579 | SLCO1A2 | TRANSPORTER, DRUGGABLE GENOME | | imatinib | IMATINIB | 21633340 |
6579 | SLCO1A2 | TRANSPORTER, DRUGGABLE GENOME | | 178101232 | | |